Fundraising FoxPack Ventures — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists.
AI & Machine LearningBiotechDeep TechSeattle, US
Matthew Bick(Executive Officer, Director, Promoter)inJavier Castellanos(Executive Officer, Director, Promoter)inHector De Jesus Rincon Arano(Executive Officer, Promoter)Heather Redman(Director)Randall Schatzman(Director)William Canestaro(Executive Officer)in
PartnerKen Horenstein· solo GP
Co-investorsCreative Destruction Lab (CDL)Flying Fish VenturesArgonautic VenturesColumbus Venture PartnersWRF Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.